🇺🇸 FDA
Pipeline program

LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810

R2810-ONC-1788

Phase 3 small_molecule active

Quick answer

LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810 for Cutaneous Squamous Cell Carcinoma (CSCC) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Cutaneous Squamous Cell Carcinoma (CSCC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials